Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knees osteoarthritis and rheumatoid arthritis

Osteoarthritis and Cartilage

Volumn 12, Issue 6, 2004, Pages 440-447

  Rousseau, J C ^a   Zhu, Y ^b   Miossec, P ^a   Vignon, E ^c   Sandell, L J ^b   Garnero, P ^a,d   Delmas, P D ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b BARNES JEWISH HOSPITAL   (United States)

^c Hôpital Sud   (France)

^d Synarc   (France)

Author keywords

N propeptide IIA; Osteoarthritis; Rheumatoid arthritis; Type II collagen

Indexed keywords

ANTIGEN; COLLAGEN TYPE 2; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; POLYCLONAL ANTIBODY; PREDNISONE; PROCOLLAGEN; PROCOLLAGEN N PROTEINASE; PROTEIN ANTIBODY; PROTEIN SUBUNIT; THROMBOSPONDIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CROSS REACTION; DIAGNOSTIC ACCURACY; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; KNEE OSTEOARTHRITIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PURIFICATION; RHEUMATOID ARTHRITIS; SEQUENCE HOMOLOGY; SYNOVIAL FLUID; WESTERN BLOTTING;

EID: 2542551882     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2004.02.004     Document Type: Article

References (41)

1. Mankin HJ, Dorfman H, Lippiello L, Zarin A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. J Bone Joint Surg Am 1971;53:523-37.
2. Eyre D, McDewitt CA, Billingham ME, Muir H. Biosynthesis of collagen and other matrix proteins by articular cartilage in experimental osteoarthritis. Biochem J 1980;188:823-37.
3. Carney SL, Billingham MEJ, Muir H, Sandy JD. Demonstration of increased proteoglycan turnover in cartilage explants from dogs with experimental osteoarthritis. J Ortho Res 1984;2:201-6.
4. Sandy JD, Adams ME, Billingham ME, Plaas A, Muir H. In vivo and in vitro stimulation of chondrocyte biosynthetic activity in early experimental osteoarthritis. Arthritis Rheum 1984;27:388-97.
5. Matyas JR, Adams ME, Huang DQ, Sandell LJ. Discoordinate gene expression of aggrecan and type II collagen in experimental osteoarthritis. Arthritis Rheum 1995;38:420-5.
6. Lohmander LS, Yoshihara Y, Roos H, Kobayashi T, Yamada H, Shinmei M. Procollagen II-C propeptide in joint fluid: changes in concentration with age, time after injury and osteoarthritis. J Rheumatol 1996; 23:1765-9.
7. Cs-Szabo G, Melching LI, Roughley PJ, Glant TT. Changes in messenger RNA and protein levels of proteoglycans and link protein in human osteoarthritic cartilage samples. Arthritis Rheum 1997; 40:1037-45.
8. Aigner T, Gluckert K, von der mark K. Activation of fibrillar collagen synthesis and phenotypic modulation of chondrocytes in early human osteoarthritis cartilage lesions. Osteoarthr Cart 1997;5:183-9.
9. Salminen H, Perala M, Lorenzo P, Saxne T, Heinegard D, Saamanen AM. Up-regulation of cartilage oligomeric matrix protein at the onset of articular cartilage degeneration in a transgenic mouse model of osteoarthritis. Arthritis and Rheum 2000;43:1742-8.
10. van der Rest M, Garrone R. Collagen family of proteins. FASEB J 1991;5:2814-23.
11. Garnero P, Delmas PD. Laboratory assessment of postmenopausal osteoporosis. In: Seibel MJ, Robins SP, Bilezikian JP, Eds. Dynamics of bone and cartilage metabolism, principles and clinical applications. San Diego, CA: Academic Press 1998;465-77.
12. Shinmei M, Ito K, Matsuyama S, Yoshihara Y, Matsuzawa K. Joint fluid carboxy-terminal type II procollagen peptide as a marker of cartilage biosynthesis. Osteoarthr Cart 1993;Apr.,1(2):121-8.
13. Mansson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AR, et al. Cartilage and bone metabolism in rheumatoid arthritis: differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995; 95:1071-77.
14. Nelson F, Dahlberg L, Laverty S, Reiner A, Pidoux I, Ionescu M, et al. Evidence for altered synthesis of type II collagen patients with osteoarthritis. J Clin Invest 1998;102:2115-25.
15. Sandell LJ, Morris N, Robbins JR, Goldring MR. Alternatively spliced type II procollagen mRNAs define distinct populations of cells during vertebral development: differential expression of the amino-propeptide. J Cell Biol 1991;114:1307-19.
16. Ng LJ, Tam PP, Cheah KSE. Preferential expression of alternatively spliced mRNAs encoding type II procollagen with a cysteine-rich amino-propeptide in differentiating cartilage and nonchondrogenic tissues during early mouse development. Dev Biol 1993; 159:403-17.
17. Sandell LJ, Nalin A, Reife R. Alternative splice form of type II procollagen mRNA (IIA) is predominant in skeletal precursors and non-cartilaginous tissues during early mouse development. Dev Dyn 1994; 199:129-40.
18. Matyas JR, Sandell LJ, Adams ME. Gene expression of type II collagens in chondro-osteophytes in experimental osteoarthritis. Osteoarthr Cart 1997; 5:99-105.
19. Hughes SS, Hicks DG, O'Keefe RJ, Hurwitz SR, Crabb ID, Krasinskas AM, et al. Shared phenotypic expression of osteoblasts and chondrocytes in fracture callus. J Bone Miner Res 1995;10:533-44.
20. Aigner T, Zhu Y, Chansky HH, Martsen FA, Maloney W, Sandell LJ. Reexpression of type IIA procollagen by adult articular chondrocytes in osteoarthritic cartilage. Arthritis Rheum 1999;42:1443-50.
21. Nah YN, Swoboda B, Birk DE, Kirsch T. Type IIA procollagen: expression in developing chicken limb cartilage and human osteoarthritic articular cartilage. Dev Dyn 2001;220:307-22.
22. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11:337-49.
23. Szulc P, Marchand F, Duboeuf F, Delmas PD. Cross-sectional assessment of age-related bone loss in men: the MINOS study. Bone 2000;26:123-9.
24. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29:1039-49.
25. Bellamy N, Buchanan WW, Goldmisth CH, Campbell SLW. Validation of the WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
26. Arnett FC, Edworthy SM, Block DJ, McShane JF, Fries NS, Cooper LA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
27. Oganesian A, Zhu Y, Sandell LJ. Type IIA procollagen aminopropeptide is localized in human embryonic tissues. J Histochem Cytochem 1997;45:1469-80.
28. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, et al. Immunoassay for intact aminoterminal propeptide of human type I procollagen (PINP). Cli Chem 1996;42:947-54.
29. Podell DN, Abraham GN. A technique for the removal of pyroglutamic acid from the amino terminus of proteins using calf liver pyroglutamate amino peptidase. Biochem Biophys Res Commun 1978; 81:176-85.
30. Fukui N, McAliden A, Zhu Y, Crouch E, Broekelmann TJ, Mecham RP, et al. Processing of type II procollagen aminopropeptide by matrix metalloproteinases. J Biol Chem 2002;277:2193-201.
31. Ryan MC, Sandell LJ. Differential expression of a cysteine-rich domain in the amino-terminal propeptide of type II (cartilage) procollagen by alternative splicing of mRNA. J Biol Chem 1990;265:10334-9.
32. Matyas JR, Adams ME, Dinqqin H, Sandell L. Major role of collagen IIB in the elevation of total type II procollagen messenger RNA in the hypertrophic phase of experimental osteoarthritis. Arthritis Rheum 1997;40:1046-9.
33. van der Kraan PM, Vitters EL, Meijers TH, Poole AR, van der Berg WB. Collagen type I antisense and collagen type IIA messenger RNA is expressed in adult murine articular cartilage. Osteoarthr Cart 1998; 6:417-26.
34. Rebuck N, Croucher LJ, Hollander AP. Distribution of two alternatively spliced variants of type II collagen N-propeptide compared with the C-propeptide in bovine chondrocyte pellet cultures. J Cell Biochem 1999;75:13-21.
35. Reardon AJ, Sandell LJ, Jones CJ, McLeod D, Bishop PN. Localisation of pN-type IIA procollagen on adult bovine vitreous collagen fibrils. Matrix Biol 2000; 19:169-73.
36. Bishop PN, Reardon AJ, McLeod D, Ayad S. Identification of alternatively spliced variants of type II procollagen in vitreous. Biochem Biophys Res Commun 1994;203:289-95.
37. Zhu Y, McAliden A, Sandell LJ. Type IIA procollagen in development of the human intervertebral disc: regulated expression of the NH2-propeptide by enzymatic processing reveals a unique developmental pathway. Dev Dyn 2001;220:350-62.
38. Garnero P, Ayral X, Rousseau J-C, Christgau S, Sandell LJ, Dougados M, et al. Uncoupling of type II collagen and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002;46:2613-24.
39. Deleuran BW, Chu CQ, Field M, Brennan FM, Katsikis P, Feldmann M, et al. Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 1992;31:801-9.
40. Farahat MN, Yanni G, Poston R, Panayi GS. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1993;52:870-5.
41. Miller VE, Rogers K, Muirden KD. Detection of tumour necrosis factor alpha and interleukin-1 beta in the rheumatoid osteoarthritic cartilage-pannus junction by immunohistochemical methods. Rheumatol Int 1993;13:77-82.